ACTIVATION OF BP1 IS ASSOCIATED WITH AGGRESSIVE BREAST CANCER PATRICIA BERG, PH.D.

Slides:



Advertisements
Similar presentations
TOP2A IS AN INDEPENDENT PREDICTOR OF SURVIVAL IN UNSELECTED BREAST CANCER Amit Pancholi Molecular Profiling of Breast Cancer: Predictive Markers of Long.
Advertisements

Fundamental research on breast cancer in Belgium Rosita Winkler.
Tumor Markers Lecture one By Dr. Reem Sallam. Objectives  To briefly introduce cancers, their incidence, some common terms, and staging system.  To.
Cancer Genetics Is Cancer a Genetic Disease? Cancer is not a classic genetic disease, instead, Genetic background (set-up) has a definite role in cancer.
Cancer.
Regulated Splicing Changes are Associated with Tumor Type and Grade Exon specific array from 3 lymphoma cell lines (IV, IVb and III) and non-tumor B cell.
MDM2: Oncogene Chan Lee. Discovery of MDM2: starting with tumor suppressor p53.
Hallmarks of Cancer Six fundamental changes 1.Self sufficiency in growth factors 2.Insensitivity to growth-inhibitory signals 3.Evasion of apoptosis 4.Limitless.
 MicroRNAs (miRNAs) are a class of small RNA molecules, about ~21 nucleotide (nt) long.  MicroRNA are small non coding RNAs (ncRNAs) that regulate.
Targeted Therapy: A Giant Step Forward
Breast Cancers With Brain Metastases are More Likely to be Estrogen Receptor Negative, Express the Basal Cytokeratin CK5/6, and Overexpress HER2 or EGFR.
What is Cancer? How it occurs and cell cycle regulation.
Understanding and Optimizing Treatment of Triple Negative Breast Cancer Edith Peterson Mitchell, MD, FACP Clinical Professor of Medicine and Medical Oncology.
Metastatic Breast Cancer: One Size Does Not Fit All Clifford Hudis, M.D. Chief, Breast Cancer Medicine Service MSKCC.
Genetic and Molecular Epidemiology
Cancer: when our own cells become the enemy
Amplification of COPS3 in High-grade Osteosarcoma: Relationship to TP53 Mutation and Patient Outcome Samuel Lunenfeld Research Institute Mount Sinai Hospital,
Cell Cycle and Cancer. Cancer Terms Neoplasm – new, abnormal growth of cells Benign – not cancerous Malignant - cancerous Cancer – cellular growth disorder.
Advanced Cancer Topics Journal Review 4/16/2009 AD.
Table S1. Characteristics of breast tumor and normal breast tissue samples. Relevant characteristics of breast tumor and normal breast tissue samples analyzed.
Changes in Tumor Growth and Metastatic Capacities of J82 Human Bladder Cancer Cells Suppressed by Down-regulation of Calreticulin Expression Speaker: Yi-Chien.
Cancer Uncontrolled cell growth. Cellular differentiation is the process by which a less specialized cell becomes a more specialized cell type. Occurs.
Cancer --an Overview  Cell Division  Hormones and Cancer  Malignant Transformation  Angiogenesis and Metastasis  Growth.
Metastatic Cancer – Gross Pathology Lymph node - metastasis from breastLiver – metastasis from lung Vertebral column – metastasis from prostate Mesentery.
Changes in Breast Cancer Reports After Second Opinion Dr. Vicente Marco Department of Pathology Hospital Quiron Barcelona. Spain.
Poster Discussion 2 - Biology Genome Transcriptome Proteome Metastasome.
Functional interactions between calmodulin and estrogen receptor-α
Essentials of Biology Sylvia S. Mader
CONTROLLING GENE EXPRESSION CHAPTER 11. GENE EXPRESSION - occurs in the DNA the activation of a gene that results in the formation of a protein. The gene.
Potential therapeutic target & predictive biomarker Oncogenic IGFBP2 Sonya Song ( 宋韦 ) Beijing Shijitan Hospital Department of Oncology The Capital Medical.
ROLE OF GENE EXPRESSION:  Activation of a gene that results in a protein  Cells DO NOT need to produce proteins for every code. GENOME:  Complete genetic.
Cancer Basics EQ: What does cancer have to do with the cell cycle?
Understanding Cancer and Related Topics
Breast Cancer. Breast cancer is a disease in which malignant cells form in the tissues of the breast – “National Breast Cancer Foundation” The American.
EXPRESSION OF HER-2 CORRELATED PROTEINS IN ILEAL CARCINOIDS Azzoni C., Giordano G., Bottarelli L., Tamburini E., D’Adda T., Pizzi S., Rindi G., Bordi C.
CONTROLLING GENE EXPRESSION CHAPTER 11. GENE EXPRESSION - occurs in the DNA- prior to TRANSCRIPTION the activation of a gene that results in the formation.
Relationship Between STAT3 Inhibition and the Presence of p53 on Cyclin D1 Gene Expression in Human Breast Cancer Cell Lines Introduction STAT3 and p53.
Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer Slideset on: Piccart-Gebhart M, Procter M, Leyland- Jones B, et al. Trastuzumab.
Understanding Cancer Developed by: Lewis J. Kleinsmith, Ph.D., Donna Kerrigan, M.S., Jeanne Kelly, Brian Hollen Lesson Objectives: Illustrate what cancer.
The Problem of Cancer. What are cancer cells ? Cancerous growth involves unrestrained proliferation (malignancy) and spread (metastasis). Caused by: mutations.
Comparison between Pathologic Characteristics of Her2 Negative and Positive Breast Cancer in a Single Cancer Center in Jordan DR Majdi A. Al Soudi, MD,
Mouse Double Minute 2 (MDM2)
Monica Britton, Ph.D. Sr. Bioinformatics Analyst June 2016 Workshop
Genetics In Breast Cancer
Cancer unchecked growth that progresses toward limitless expansion.
Yu-fang huang, yi-hui wu, cheng-yang chou*
Figure 1. MORT gene silencing is early event in cancer
A Functional Map of Oncogenic States for Breast Cancer
Cancer.
Concept 18.5: Cancer results from genetic changes that affect cell cycle control The gene regulation systems that go wrong during cancer are the very same.
Sp1 Suppresses miR-3178 to Promote the Metastasis Invasion Cascade via Upregulation of TRIOBP  Hui Wang, Kai Li, Yu Mei, Xuemei Huang, Zhenglin Li, Qingzhu.
Up-Regulation of RFC3 Promotes Triple Negative Breast Cancer Metastasis and is Associated With Poor Prognosis Via EMT  Zhen-Yu He, San-Gang Wu, Fang Peng,
UHRF1 is regulated by miR-9 in colorectal cancer
Figure 1 A schematic representation of the HER2 signalling pathway
Regulation of the Cell Cycle
by Douglas D. Ross, Judith E. Karp, Tar T. Chen, and L. Austin Doyle
Volume 17, Issue 4, Pages (April 2010)
NRP2 represses IGF-IR expression and signaling.
Transcription Initiation:
Volume 17, Issue 4, Pages (April 2010)
Volume 117, Issue 7, Pages (June 2004)
Volume 19, Issue 8, Pages (August 2011)
Shipra Das, Olga Anczuków, Martin Akerman, Adrian R. Krainer 
FAK overexpression in invasive human breast cancer and DCIS
IL6 mRNA is not detected in metastatic prostate cancer cells.
The Role of TIPE2 Protein in Invasive Breast Carcinoma
Model of malignant transformation of in vitro HBECs following stepwise introduction of common lung cancer mutations. Model of malignant transformation.
Targeting GAPLINC decreased CD44 expression and tumor growth in vivo.
B7-H3 Associated with Tumor Progression and Epigenetic Regulatory Activity in Cutaneous Melanoma  Jinhua Wang, Kelly K. Chong, Yoshitaka Nakamura, Linhda.
Presentation transcript:

ACTIVATION OF BP1 IS ASSOCIATED WITH AGGRESSIVE BREAST CANCER PATRICIA BERG, PH.D.

pBP1 IS AN ISOFORM OF THE DLX4 GENE CHASE ET AL, MOL. CELL. BIOL. 22: NOTE: BP1 AND DLX4 ARE NOT INTERCHANGEABLE TERMS BP1 DLX7 DLX4

CHARACTERISTICS OF BP1 BELONGS TO THE DISTAL-LESS (DLX) FAMILY DLX GENES ARE HIGHLY CONSERVED: FOUND IN DROSOPHILA, ZEBRAFISH, FROGS, CHICKENS, MICE AND HUMANS IMPORTANT FOR CRANIOFACIAL, LIMB, TOOTH AND OCULAR DEVELOPMENT IN MICE

CHARACTERISTICS OF BP1 (CONT) ENCODES A TRANSCRIPTION FACTOR THAT REGULATES CASCADES OF GENES, INCLUDING ONCOGENES A POTENTIAL ONCOGENE ACTIVATED IN A NUMBER OF DIFFERENT TYPES OF CANCER

ACTIVATION OF BP1 IN CANCER BREAST CANCER – 80% (FU ET AL, 2003) PROSTATE CANCER – 70% (SCHWARTZ ET AL, 2005) ACUTE MYELOID LEUKEMIA – 63% (HAGA ET AL, 2000)

ACTIVATION OF BP1 IN CANCER (CONT) OVARIAN CANCER – ~ 65% ( and HARA ET AL, 2007 ) LUNG CANCER – ~ 45% ( and YU ET AL, 2008) COLON CANCER – ~40% Berg, PE and Kirolikar, S Atlas Genet Cytogenet Oncol Haematol. 15:

GENES INVOLVED IN NON- HEREDITARY BREAST CANCER GENEFREQUENCY HER-220 – 30% C-MYC20 – 30% CYCLIN E30% EGFR25-35% CYCLIN D1 BP1 50% (20% AMPLIFIED) 80%

ASSOCIATION BETWEEN BP1 mRNA EXPRESSION AND CLINICO-PATHOLOGICAL DATA BP1 mRNA Factors Negative Positive p value ER Status 0.03 Negative0 (0%) 18 (100%) Positive7 (27%) 19 (73%) PR Status 0.02 Negative1 (4.0%) 24 (96%) Positive6 (33%) 12 (67%) Race 0.04 Caucasian6 (43%) 8 (57%) African American3 (11%) 25 (89%) FU et al, Br. Ca. Res. 5:

BP1 AND BREAST CANCER PROGRESSION MAN ET AL, BR. CA. RES. & TREAT. 90:

BP1 and Progression NORMAL HYPERPLASIA (IDH) DUCTAL CARCINOMA IN SITU (DCIS) INVASIVE DUCTAL CARCINOMA (IDC) 0% 21% n=70 46% n=100 81% n=100 N 0% n=30

SUMMARY AS TUMOR PROGRESSION OCCURS, THERE IS AN INCREASE IN 1. THE PERCENTAGE OF BP1 POSITIVE TUMORS 2. THE PERCENTAGE OF BP1 POSITIVE CELLS PER TUMOR 3. BP1 STAINING INTENSITY (BP1 EXPRESSION)

INFLAMMATORY BREAST CANCER RAPIDLY PROGRESSIVE HIGHLY ANGIOGENIC AND INVASIVE 5 YR SURVIVAL LESS THAN 45% VS 86% IN NON-IBC LESS THAN HALF HAVE A DISCRETE MASS REPRESENT 1-5% OF ALL BREAST CANCERS IN CAUCASIANS AND 10% IN AFRICAN AMERICANS

BP1 AND INFLAMMATORY BREAST CANCER 100% OF IBC TUMORS WERE BP1 POSITIVE (N=45) WITH 95% OF CELLS POSITIVE 9 PAIRED METASTATIC LYMPH NODES AVAILABLE; ALL WERE BP1 POSITIVE TUMOR CELLS IN BLOOD VESSELS AND LYMPHATIC CHANNELS WERE BP1 POSITIVE Man et al, Ca. Biomarkers 5: 9-17.

BP1 EXPRESSION IN LYMPHATIC CHANNELS AND BLOOD VESSELS LYMPHATIC CHANNELS BLOOD VESSELS

HOW IS BP1 ACTIVATED? A. DNA AMPLIFICATION B. ESTRADIOL

A. DNA AMPLIFICATION AMPLIFICATION OF BP1 WAS OBSERVED BY FISH IN 22% OF PRIMARY BREAST TUMORS AND IN 24% of MATCHED SLN METASTASES FROM PATIENTS WITH INVASIVE DUCTAL BREAST CANCER* NOTE: BP1 MAPS TO 17Q21-22** * TORRESON ET AL, 2014; CAVALLI ET AL, ** FU ET AL, GENE 278:

FISH analysis of FFPE sections of a primary breast tumor (left) and SLN metastasis (right) from one patient showing amplification of the BP1 gene FISH ANALYSIS OF BP1

CORRELATION BETWEEN BP1 AMPLIFICATION AND EXPRESSION ALL CASES SHOWING BP1 AMPLIFICATION ALSO SHOWED BP1 EXPRESSION BY IHC BP1 POSITIVITY WAS ALSO SEEN IN CASES WITHOUT AMPLIFICATION

BP1 AND HER2 BP1 AND HER2 MAP NEAR EACH OTHER AND ARE CO-AMPLIFIED 78% OF THE TIME IN PRIMARY TUMORS AND 100% OF THE TIME IN SLN

B. ESTRADIOL STIMULATES BP1 IN MCF7 CELLS ERα BINDS TO BP1 INTRON I ChIP 1. LADDER 2.3 INPUT CONTROL FOR ERE ELEMENT IN EXON I AND INTRON I 4.5 AFTER IP WITH ERα AB

BP1 ACTIVATES ONCOGENES GENEASSOCIATED WITH MMP9INITIATION, INVASION, METASTASIS BCL-2ANTI-APOPTOTIC (Stevenson et al, 2007) C-MYCPROLIFERATION, DIFFERENTIATION, APOPTOSIS (Trinh et al, 2011) MET VEGF GROWTH, ANGIOGENESIS, METASTASIS ANGIOGENESIS (Hara et al, 2007)

BP1 EXPRESSION IS ASSOCIATED WITH AGGRESSIVENESS

MEASURES OF AGGRESSIVENESS BP1 INCREASES: GROWTH IN THE ABSENCE OF SERUM GROWTH IN SOFT AGAR (ANCHORAGE INDEPENDENT GROWTH) INVASION THROUGH MATRIGEL CHANGES IN TUMOR FORMATION IN NUDE MICE

O4 O2 V1 D4D13 GROWTH IN SOFT AGAR

CELL LINES OVEREXPRESSING BP1 WERE INJECTED INTO THE FAT PADS OF NUDE MICE Submitted

EFFECT OF BP1 ON TUMOR GROWTH IN MICE

ESTROGEN INDEPENDENT TUMOR FORMATION IN MICE Cell Type InjectedEstrogen added Absence of Estrogen MCF-7/EV-14/10 (40%)0/10 (0%) MCF-7/BP1-210/15 (67%)2/10 (20%) MCF-7/BP1-47/11 (64%)2/10 (20%)

BP1 UPREGULATES ERα BOTH DIRECTLY AND INDIRECTLY SUBMITTED

DIRECT: BP1 ACTIVATES ERα RNA BY BINDING TO IVS1

INDIRECT: BP1 STABILIZES ERα BY UPREGULATING p300 (p300 ACETYLATES ERα) p300 ACTIN O1 V1 mRNA PROTEIN

INDIRECT: BP1 AND BRCA1 BRCA1 INHIBITS ERα PROTEIN VIA UBIQUITINATION BP1 REPRESSES BRCA1 BY BINDING TO ITS FIRST INTRON (Kluk et al, 2010), WHICH IS PREDICTED TO FURTHER INCREASE THE LEVEL OF ERα

MODEL

CONCLUSIONS BP1 EXPRESSION MAY BE PROGNOSTIC IN BREAST CANCER BP1 IS A NEW POTENTIAL THERAPEUTIC TARGET

ACKNOWLEDGEMENTS GWUMC SAURABH KIROLIKAR JHU SANKET AWATE JUDITH KARP DANIEL RHEEY FARHAD VESUNA BIN JIN HUANG VENU RAMAN KELLIE YAMANE YASSI FALLAH AFIP YAN-GAO MAN ARNOLD SCHWARTZ PAUL LEVINE GEORGETOWN SAMUEL SIMMENSLUCIANE CAVALLI SIDNEY FU DAVID GEFFEN SOM NCI BARBARAJOSEPH PINZONE VONDERHAAR